ライフサイエンスコーパス: nosocomial pneumonia

1 y morbidity (a composite measure of ARDS and nosocomial pneumonia).

2 t of hospital-related infections, especially nosocomial pneumonia.

3 ae were made available for all patients with nosocomial pneumonia.

4 ne whether prophylaxis increases the risk of nosocomial pneumonia.

5 on-inferior to meropenem in the treatment of nosocomial pneumonia.

6 viders caring for hospitalized patients with nosocomial pneumonia.

7 MEDI4893 and MEDI3902, for the prevention of nosocomial pneumonia.

8 illin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia.

9 ression syndrome and to decrease the rate of nosocomial pneumonia.

10 an etiologic agent of community-acquired and nosocomial pneumonia.

11 ions between MRSA virulence and mortality in nosocomial pneumonia.

12 R Acinetobacter infections, particularly for nosocomial pneumonia.

13 d patients, and assessed its relationship to nosocomial pneumonia.

14 of selenium on ICU length of stay or risk of nosocomial pneumonia.

15 ed amikacin for critically ill patients with nosocomial pneumonia.

16 Thirteen (41%) patients developed nosocomial pneumonia.

17 zolid versus vancomycin for the treatment of nosocomial pneumonia.

18 hylococcus aureus (MRSA) is a major cause of nosocomial pneumonia.

19 ed vancomycin regimen, for treatment of MRSA nosocomial pneumonia.

20 illin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia.

21 in achieving clinical cure in patients with nosocomial pneumonia.

22 e with improved efficacy in the treatment of nosocomial pneumonia.

23 eruginosa contributes to the pathogenesis of nosocomial pneumonia.

24 an important pathogen in cystic fibrosis and nosocomial pneumonia.

25 sus meropenem for treatment of Gram-negative nosocomial pneumonia.

26 toward reductions in ICU length of stay and nosocomial pneumonia.

27 nst Pseudomonas aeruginosa, a major cause of nosocomial pneumonia.

28 Pseudomonas aeruginosa is a leading cause of nosocomial pneumonia.

29 Pseudomonas aeruginosa is a leading cause of nosocomial pneumonia.

30 ch as Escherichia coli, are common causes of nosocomial pneumonia.

31 ty of patients in the intensive care unit to nosocomial pneumonia.

32 Disease Control and Prevention definition of nosocomial pneumonia.

33 us sequelae, particularly the development of nosocomial pneumonia.

34 for a significant proportion of episodes of nosocomial pneumonia.

35 tract infections and an occasional cause of nosocomial pneumonia.

36 iratory pathogen colonization and subsequent nosocomial pneumonia.

37 most frequent Gram-negative pathogen causing nosocomial pneumonia.

38 e have positive effects on the prevention of nosocomial pneumonias.

39 was lower in brain-injured patients without nosocomial pneumonia (1% [range: 0%-7%]) and in brain-in

40 compared with brain-injured patients without nosocomial pneumonia (16% [range: 6%-29%]) and with heal

41 ly altered in brain-injured patients without nosocomial pneumonia (26% [range: 10%-41%]).

42 tly decreased in brain-injured patients with nosocomial pneumonia (3% [range: 1%-9%]) compared with b

43 s not altered in brain-injured patients with nosocomial pneumonia (31% [range: 12%-44%]).

44 : 0%-7%]) and in brain-injured patients with nosocomial pneumonia (4% [range: 2%-5%]) compared with h

45 . 3.4 days; p = .09) and higher incidence of nosocomial pneumonia (42 vs. 21% p = .08).

46 ntly decreased in brain injury patients with nosocomial pneumonia (5% [range: 4%-43%]) compared with

47 increased in brain-injured patients without nosocomial pneumonia (66% [range: 34%-69%]) compared wit

48 nalysis demonstrated that the development of nosocomial pneumonia (adjusted odds ratio [AOR], 4.72; 9

49 ion (block size four), stratified by type of nosocomial pneumonia and age (<65 years vs >=65 years),

50 nas aeruginosa (P. aeruginosa) is crucial in nosocomial pneumonia and in chronic lung infections.

51 ciated with skin and soft tissue infections, nosocomial pneumonia and sepsis.

52 of doripenem in critically ill patients with nosocomial pneumonia and then to use Monte Carlo dosing

53 compared with brain-injured patients without nosocomial pneumonia and with healthy donors.

54 secondary outcomes were ICU length of stay, nosocomial pneumonia, and adverse events.

55 revious studies suggest an increased risk of nosocomial pneumonia associated with the use of H2-recep

56 of complicated urinary tract infections and nosocomial pneumonia based on clinical trials that demon

57 as different diseases such as community and nosocomial pneumonia, bloodstream infections, endocardit

58 l trial (CREDIBLE-CR) in patients with cUTI, nosocomial pneumonia, bloodstream infections, or sepsis

59 For the treatment of MRSA nosocomial pneumonia, clinical response at EOS in the PP

60 in the settings of cystic fibrosis (CF) and nosocomial pneumonia could be exceedingly useful, but to

61 zolid vs. glycopeptides for the treatment of nosocomial pneumonia despite a statistical power of 95%.

62 ased acid secretion could be responsible for nosocomial pneumonia developing in critically ill intens

63 ng that a gold standard for the diagnosis of nosocomial pneumonia does not exist.

64 Nosocomial pneumonia due to antimicrobial-resistant path

65 uble-blind trial (APEKS-NP) in patients with nosocomial pneumonia due to carbapenem-susceptible gram-

66 e undergoing mechanical ventilation, and had nosocomial pneumonia (either ventilator-associated pneum

67 Patients with nosocomial pneumonia exhibit elevated levels of neurotox

68 domonas aeruginosa in 5 patients treated for nosocomial pneumonia for 10-28 days.

69 clear cells from brain-injured patients with nosocomial pneumonia generated significantly fewer matur

70 intestinal bleeding; secondary outcomes were nosocomial pneumonia, ICU mortality, ICU length of stay,

71 rt study of the epidemiology and etiology of nosocomial pneumonia in 358 medical ICU patients in two

72 The strongest predictor for nosocomial pneumonia in both the surgical and medical/re

73 have been associated with increased risk for nosocomial pneumonia in hospitalized patients.

74 d well tolerated treatment for Gram-negative nosocomial pneumonia in mechanically ventilated patients

75 L micdadei is the cause of nosocomial pneumonia in renal transplant recipients, but

76 es when given for the empirical treatment of nosocomial pneumonia in the absence of methicillin-resis

77 couraged to confirm these characteristics of nosocomial pneumonia in the injured child.

78 In a public teaching hospital, all cases of nosocomial pneumonia in the surgical and medical/respira

79 of the study was to examine risk factors for nosocomial pneumonia in the surgical and medical/respira

80 ACHE III score was found to be predictive of nosocomial pneumonia in the surgical ICU population, but

81 To describe the epidemiology of nosocomial pneumonia in trauma patients and its impact o

82 Except for more nosocomial pneumonias in the G-CSF patients (7 in 114 pa

83 Adults with nosocomial pneumonia (including ventilator-associated pn

84 alternative to carbapenems in patients with nosocomial pneumonia (including ventilator-associated pn

85 ty of ceftazidime-avibactam in patients with nosocomial pneumonia, including ventilator-associated pn

86 natants or CSF from patients with or without nosocomial pneumonia indicated that endothelium-derived

87 Nosocomial pneumonia is commonly associated with antimic

88 n of the airway, suggesting that the risk of nosocomial pneumonia is unlikely to be increased during

89 Klebsiella pneumoniae, a chief cause of nosocomial pneumonia, is a versatile and commonly multid

90 dults admitted to an index hospital with non-nosocomial pneumonia (January through December 2010) and

91 jured patients would affect the incidence of nosocomial pneumonia, length of stay, and hospital charg

92 tiple clinical descriptions of S. marcescens nosocomial pneumonia, little is known regarding the mech

93 nary tract infections, abdominal infections, nosocomial pneumonia, neonatal meningitis, and sepsis.

94 role of periodontitis in the development of nosocomial pneumonia (NP) have been published, the debat

95 Nosocomial pneumonia (NP) is a difficult diagnosis to es

96 s study of a single pediatric trauma center, nosocomial pneumonia occurred in a small but significant

97 3; 95% CI, -0.51, 4.56; p = 0.12; I = 0%) or nosocomial pneumonia (odds ratio, 0.83; 95% CI, 0.28, 2.

98 ion may be at the greatest risk of acquiring nosocomial pneumonia of all hospitalized patients.

99 Patients who recover from nosocomial pneumonia oftentimes exhibit long-lasting cog

100 This report describes three patients with nosocomial pneumonia or tracheobronchitis due to multire

101 tamine 2 receptor antagonists in the risk of nosocomial pneumonia (relative risk 1.06; 95% confidence

102 e found to have consistently higher rates of nosocomial pneumonia than medical ICU patients (RR = 2.2

103 logical or clinical outcome in patients with nosocomial pneumonia treated with a fluoroquinolone.

104 The frequency rate of nosocomial pneumonia was 8% (8:100) in the HHME-24 group

105 The frequency rate of nosocomial pneumonia was also unchanged.

106 In 91% of patients (26 children), nosocomial pneumonia was associated with mechanical vent

107 s were associated with central lines, 86% of nosocomial pneumonia was associated with mechanical vent

108 erted increased significantly if the risk of nosocomial pneumonia was included in the analysis.

109 The frequency rate of nosocomial pneumonia was made by using clinical criteria

110 Concern for nosocomial pneumonia was regarded as more prevalent with

111 Thirty-five episodes of nosocomial pneumonia were identified in 29 children (fre

112 . vancomycin or teicoplanin for treatment of nosocomial pneumonia were included.

113 Overall, children with nosocomial pneumonia were more severely injured (Injury

114 Biopsy-proven rejection and nosocomial pneumonias were more common in patients treat